Management of the hypertensive patient with elevated heart rate: Statement of the Second Consensus Conference endorsed by the European Society of Hypertension

Journal of Hypertension

Volumn 34, Issue 5, 2016, Pages 813-821

  Palatini, Paolo ^a   Rosei, Enrico Agabiti ^b   Casiglia, Edoardo ^a   Chalmers, John ^c   Ferrari, Roberto ^d   Grassi, Guido ^e   Inoue, Teruo ^f   Jelakovic, Bojan ^g   Jensen, Magnus T ^h   Julius, Stevo ⁱ   Kjeldsen, Sverre E ^j   Mancia, Giuseppe ^e   Parati, Gianfranco ^e   Pauletto, Paolo ^a   Stella, Andrea ^k   Zanchetti, Alberto ^l  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY HOSPITAL OF FERRARA   (Italy)

^e UNIVERSITY OF MILANO BICOCCA   (Italy)

^f DOKKYO MEDICAL UNIVERSITY   (Japan)

^g KBC Zagreb   (Croatia)

^h GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^k SAN GERARDO HOSPITAL   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Cardiovascular; Heart rate; Hypertension; Measurement; Mortality; Prognosis; Risk; Sympathetic nervous system

Indexed keywords

AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; ARTICLE; CARDIOVASCULAR RISK; DRUG CHOICE; HEART RATE; HUMAN; HYPERTENSION; MEASUREMENT; PRIORITY JOURNAL; SELF EVALUATION; TACHYCARDIA; COMPLICATION; CONSENSUS DEVELOPMENT; DISEASE MANAGEMENT; EUROPE; MEDICAL SOCIETY;

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE AGENTS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; DISEASE MANAGEMENT; EUROPE; HEART RATE; HUMANS; HYPERTENSION; MONITORING, AMBULATORY; SOCIETIES, MEDICAL; TACHYCARDIA;

EID: 84961230875     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000865     Document Type: Article

References (81)

1. Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens 2006; 24:603-610
2. Vogel CU, Wolpert C, Wehling M. How to measure heart rate? Eur J Clin Pharmacol 2004; 60:461-466
3. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 1997; 11 (1):19-27
4. Erikssen J, Rodahl K. Resting heart rate in apparently healthy middleaged men. Eur J Appl Physiol 1979; 42:61-69
5. Sbarouni E, Voudris V, Georgiadou P, Hamilos M, Steg G, Fox KM, et al., Greek CLARIFY investigators. Heart rate and Beta-blockade in stable coronary artery disease in Greece. Hellenic J Cardiol 2015; 56:112-117
6. Mancia G, Parati G, Pomidossi G, Grassi G, Casadei R, Zanchetti A. Alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension 1987; 9:209-215
7. Hozawa A, Ohkubo T, Kikuya M, Ugajin T, Yamaguchi J, Asayama K, et al. Prognostic value of home heart rate for cardiovascular mortality in the general population: the Ohasama study. Am J Hypertens 2004; 17:1005-1010
8. Parati G, Stergiou GS, Asmar R, Bilo G, de Leeuw P, Imai Y, et al., ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Hum Hypertens 2010; 24:779-785
9. Palatini P, Reboldi G, Beilin LJ, Eguchi K, Imai Y, Kario K, et al. Predictive value of night-time heart rate for cardiovascular events in hypertension. The ABP-International study. Int J Cardiol 2013; 168:1490-1495
10. Johansen CD, Olsen RH, Pedersen LR, Kumarathurai P, Mouridsen MR, Binici Z, et al. Resting, night-time, and 24 h heart rate as markers of cardiovascular risk in middle-aged and elderly men and women with no apparent heart disease. Eur Heart J 2013; 34:1732-1739
11. Carlson N, Dixen U, Marott JL, Jensen MT, Jensen GB. Predictive value of casual ECG-based resting heart rate compared with resting heart rate obtained from Holter recording. Scand J Clin Lab Invest 2014; 74:163-169
12. Palatini P, Winnicki M, Santonastaso M, De Venuto G, Zanata G, Bertolo O, et al. Reproducibility of heart rate measured in the clinic and with 24-h intermittent recorders. Am J Hypertens 2000; 13:92-98
13. Facila L, Pallares V, Peset A, Perez M, Gil V, Montagud V, et al. Twentyfour-hour ambulatory heart rate and organ damage in primary hypertension. Blood Press 2010; 19:104-109
14. Palatini P, Mos L, Fania C, Benetti E, Garavelli G, Mazzer A, et al. Nighttime heart rate is a long-term predictor of microalbuminuria in subjects screened for stage 1 hypertension. J Hypertens 2015; 33 (Suppl 1):e33
15. Bohm M, Schumacher H, Schmieder RE, Mann JF, Teo K, Lonn E, et al. Resting heart rate is associated with renal disease outcomes in patients with vascular disease: results of the ONTARGET and TRANSCEND studies. J Intern Med 2015; 278:38-49
16. Bohm M, Schumacher H, Leong D, Mancia G, Unger T, Schmieder R, et al. Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. Hypertension 2015; 65:651-661
17. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Lopez Sendon JL, et al., for the Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50:823-830
18. Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension 2011; 58:745-750
19. King DE, Everett CJ, Mainous AG 3rd, Liszka HA. Long-term prognostic value of resting heart rate in subjects with prehypertension. Am J Hypertens 2006; 19:796-800
20. Gillman MW, Kannel WB, Belanger A, D'Agostino RB. Influence of heart rate on mortality among persons with hypertension: The Framingham study. Am Heart J 1993; 125:1148-1154
21. Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population. Role of age, gender, and blood pressure. Hypertension 1999; 33:44-52
22. Thomas F, Bean K, Provost JC, Guize L, Benetos A. Combined effects of pulse pressure and heart rate on cardiovascular mortality. J Hypertens 2001; 19:863-869
23. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL, et al. Predictive value of clinic and ambulatory heart rate for mortality in elderly subjects with systolic hypertension. Arch Intern Med 2002; 162:2313-2321
24. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J 2008; 29:1327-1334
25. Paul L, Hastie CE, Li WS, Harrow C, Muir S, Connell JM, et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension 2010; 55:567-574
26. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlof B, Edelman JM, et al. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J 2010; 31:2271-2279
27. Poulter NR, Dobson JE, Sever PS, Dahlof B, Wedel H, Campbell NR; ASCOT Investigators. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol 2009; 54:1154-1161
28. Julius S, Palatini P, Kjeldsen S, Zanchetti A, Weber MA, McInnes GT, et al. Tachycardia predicts cardiovascular events in the VALUE trial. Am J Cardiol 2012; 109:685-692
29. Rambihar S, Gao P, Teo K, Bohm M, Yusuf S, Lonn E. Heart rate is associated with increased risk of major cardiovascular events, cardiovascular and all-cause death in patients with stable chronic cardiovascular disease-an analysis of ONTARGET/TRANSCEND. Circulation 2010; 122:A12667
30. Saxena A, Minton D, Lee DC, Sui X, Fayad R, Lavie CJ, et al. Protective role of resting heart rate on all-cause and cardiovascular disease mortality. Mayo Clin Proc 2013; 88:1420-1426
31. Eguchi K, Hoshide S, Hishikawa J, Pickering TG, Schwartz JE, Shimada K, et al. Nocturnal nondipping of heart rate predicts cardiovascular events in hypertensive patients. J Hypertens 2009; 27:2265-2270
32. Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. Blunted heart rate dip during sleep and all-cause mortality. Arch Intern Med 2007; 167:2116-2121
33. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Telera MP, Pede S, et al. Adverse prognostic value of a blunted circadian rhythm of heart rate in essential hypertension. J Hypertens 1998; 16:1335-1343
34. Salles GF, Cardoso CR, Fonseca LL, Fiszman R, Muxfeldt ES. Prognostic significance of baseline heart rate and its interaction with beta-blocker use in resistant hypertension: a cohort study. Am J Hypertens 2013; 26:218-226
35. Menotti A, Mulder I, Nissinen A, Feskens E, Giampaoli S, Tervahauta M, et al. Cardiovascular risk factors and 10-year all-cause mortality in elderly European male populations; the FINE study. Finland, Italy, Netherlands, Elderly. Eur Heart J 2001; 22:573-579
36. Dyer AR, Persky V, Stamler J, Paul O, Shekelle RB, Berkson DM, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiological studies. Am J Epidemiol 1980; 112:736-749
37. Okamura T, HayakawaT, Kadowaki T, Kita Y,Okayama A, Elliott P, et al. Resting heart rate and cause-specific death in a 16.5-year cohort study of the Japanese general population. Am Heart J 2004; 147:1024-1032
38. Fujiura Y, Adachi H, Tsuruta M, Jacobs DR Jr, Hirai Y, Imaizumi T. Heart rate and mortality in a Japanese general population: an 18-year followup study. J Clin Epidemiol 2001; 54:495-500
39. O Hartaigh B, Gill TM, Shah I, Hughes AD, Deanfield JE, Kuh D, et al. Association between resting heart rate across the life course and allcause mortality: longitudinal findings fromtheMedical Research Council (MRC) National Survey of Health and Development (NSHD). J Epidemiol Community Health 2014; 68:883-889
40. Palatini P. Heart rate as a cardiovascular risk factor: do women differ from men? Ann Med 2001; 33:213-221
41. Hsia J, Larson JC, Ockene JK, Sarto GE, Allison MA, Hendrix SL, et al., Women's Health Initiative Research Group. Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study. BMJ 2009; 338:b219
42. Pickering TG. Modern definitions and clinical expressions of hypertension. In: Laragh JH, Brenner BM, editors. Hypertension. New York: Raven Press; 1995. pp. 17-21
43. Custodis F, Shirmer SH, Baumhakel M, Heusch G, Bohm M, Laufs U. Vascular pathophysiology in response to increased heart rate. J Am Coll Cardiol 2010; 56:1973-1983
44. Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol 2011; 8:369-379
45. Palatini P, Parati G. Persistently elevated heart rate accelerates the progression of arterial stiffness. J Hypertens 2010; 28:653-656
46. Kaplan JR, Manuck SB, Adams MR, Weingand KW, Clarkson TB. Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation 1987; 76:1364-1372
47. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226:180-182
48. Ku DN, Giddens DP, Zarins CK, Glagov S. Pulsatile flow and atherosclerosis in the human carotid bifurcation. Positive correlation between plaque location and low oscillating shear stress. Arteriosclerosis 1985; 5:293-302
49. Mangoni AA, Mircoli L, Giannattasio C, Ferrari AU, Mancia G. Heart rate-dependence of arterial distensibility in vivo. J Hypertens 1996; 14:897-901
50. Sa Cunha R, Pannier B, Benetos A, Siche JP, London GM, Mallion JM, et al. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens 1997; 15:1423-1430
51. Benetos A, Adamopoulos C, Bureau J-M, Temmar M, Labat C, Bean K, et al. Determinants of accelerated progression of arterial stiffness in normotensive and treated hypertensive subjects over a 6-year period. Circulation 2002; 105:1202-1207
52. Albaladejo P, Carusi A, Apartian A, Lacolley P, Safar M, Benetos A. Effect of chronic heart rate reduction with ivabradine on carotid and aortic structure and function in normotensive and hypertensive rats. J Vasc Res 2003; 40:320-328
53. Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ, et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17 635 subjects. J Am Coll Cardiol 2014; 63:636-646
54. Perski A, Olsson G, Landou C, de Faire U, Theorell T, Hamsten A. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 1992; 123:609-616
55. Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104:1477-1482
56. Tanaka N, Nozawa T, Yasumura Y, Futaki S, Hiramori K, Suga H. Heartrate-proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol 1990; 40:503-521
57. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med 1976; 294:1165-1170
58. Sambuceti G, Marzilli M, Marraccini P, Schneider-Eicke J, Gliozheni E, Parodi O, et al. Coronary vasoconstriction during myocardial ischemia induced by rises in metabolic demand in patients with coronary artery disease. Circulation 1997; 95:2652-2659
59. Komamura K, Shannon RP, Ihara T, Shem Y, Mirsky I, Bishop SP, et al. Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol 1993; 265 (4 Pt 2):H1119-H1131
60. Wilson JR, Douglas P, Hickey WF, Lanoce V, Ferraro N, Muhammad A, et al. Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation 1987; 75:857-867
61. Eble DM, Spinale FG. Contractile and cytoskeletal content, structure, and mRNA levels with tachycardia-induced cardiomyopathy. Am J Physiol 1995; 268 (6 Pt 2):H2426-H2439
62. Menotti A, Lanti M, Agabiti-Rosei E, Carratelli L, Cavera G, Dormi A, et al. Riskard 2005. New tools for prediction of cardiovascular disease risk derived from Italian population studies. Nutr Metab Cardiovasc Dis 2005; 15:426-440
63. Janssen I, Katzmarzyk PT, Church TS, Blair SN. The Cooper Clinic Mortality Risk Index: clinical score sheet for men. Am J Prev Med 2005; 29:194-203
64. Cooney MT, Vartiainen E, Laatikainen T, Joulevi A, Dudina A, Graham I. Simplifying cardiovascular risk estimation using resting heart rate. Eur Heart J 2010; 31:2141-2147
65. Longo LD, Fauci AS, Kasper ED, Hauser SL, Jameson JL, Loscalzo J. Harrison's principles of internal medicine, 18th ed. New York: McGraw-Hill; 2012
66. Spodick DH. Redefinition of normal sinus heart rate. Chest 1993; 104:939-941
67. Palatini P, Casiglia E, Pauletto P, Staessen J, Kaciroti N, Julius S. Relationship of tachycardia with high blood pressure and metabolic abnormalities. A Study with Mixture Analysis in three Populations. Hypertension 1997; 30:1267-1273
68. Schork NJ, Weder AB, Schork MA, Bassett DR, Julius S. Disease entities, mixed multinormal distributions, and the role of the hyperkinetic state in the pathogenesis of hypertension. Stat Med 1990; 9:301-314
69. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Metaanalysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150:784-794
70. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in postmyocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007; 28:3012-3019
71. Packer M, Bristow MR, Cohn JN, for the U.S. Carvedilol Heart Failure Study Group. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334:1349-1355
72. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372:807-816
73. Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376:875-885
74. Bohm M, Borer J, Ford I, Komajda M, Tavazzi L, Sendon JL, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102:11-22
75. Palatini P, Dorigatti F, Zaetta V, Mormino P, Mazzer A, Bortolazzi A, et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens 2006; 24:1873-1880
76. Farinaro E, Stranges S, Guglielmucci G, Iermano P, Celentano E, Cajafa A, et al. Heart rate as a risk factor in hypertensive individuals. The Italian Tensiopulse Study. Nutr Metab Cardiovasc Dis 1999; 9:196-202
77. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol 2007; 50:563-572
78. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008; 52:1482-1489
79. Brook RD, Appel LJ, Rubenfire M, Ogedegbe G, Bisognano JD, Elliott WJ, et al., American Heart Association Professional Education Committee of the Council for High Blood Pressure Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, and Council on Nutrition, Physical Activity. Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the American Heart Association. Hypertension 2013; 61:1360-1383
80. Palatini P. Cardiovascular effects of exercise in young hypertensives. Int J Sports Med 2012; 33:683-690
81. Garber CE, Blissmer B, Deschenes MR, Franklin BA, Lamonte MJ, Lee IM, et al., American College of Sports Medicine. American College of Sports Medicine position stand. Quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011; 43:1334-1359